In an Australian first, cancer patients 1,000kms from a capital city now have access to a new nuclear medicine imaging agent that could help to save lives. Patients being treated for prostate cancer in Mackay are the first in Queensland and one of the most remote communities worldwide to be offered diagnostic imaging with Illuccix, the first and only PSMA-PET/CT agent to be registered by Australia's Therapeutic Goods Administration for the diagnosis of prostate cancer. CEO of Prostate Cancer Foundation of Australia, Anne Savage, hailed the development a game-changer for regional cancer care in Queensland, and Australia more broadly.

https://www.miragenews.com/world-class-care-closer-to-home-1062953/

#miragenews